SLS
NASDAQ · Biotechnology
Sellas Life Sciences Group I
$4.93
-0.02 (-0.40%)
Open$4.95
Previous Close$4.95
Day High$5.03
Day Low$4.88
52W High$6.14
52W Low$1.36
Volume—
Avg Volume4.15M
Market Cap899.71M
P/E Ratio—
EPS$-0.25
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+587.6% upside
Current
$4.93
$4.93
Target
$33.90
$33.90
$25.20
$33.90 avg
$43.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 353.66M | 369.01M | 305.89M |
| Net Income | 19.39M | 21.88M | 20.34M |
| Profit Margin | 5.5% | 5.9% | 6.7% |
| EBITDA | 24.66M | 25.78M | 21.04M |
| Free Cash Flow | 20.13M | 23.20M | 18.29M |
| Rev Growth | -7.4% | -1.2% | +17.7% |
| Debt/Equity | 0.38 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |